A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab

BACKGROUND: Hypereosinophilic dermatitis (HED) is a subtype of hypereosinophilic syndrome (HES). Glucocorticoids are preferred for treatment but carry substantial side effect profiles. Symptoms of HED may recur after systemic glucocorticoid tapering. As an interleukin-4 receptor (IL-4Rα) monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xiaoyun, Ye, Jun, Wu, Xia, Zhu, Jiang, Chen, Siji, Cheng, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010203/
https://www.ncbi.nlm.nih.gov/pubmed/36912915
http://dx.doi.org/10.1007/s00011-023-01715-1
_version_ 1784906142923620352
author Jiang, Xiaoyun
Ye, Jun
Wu, Xia
Zhu, Jiang
Chen, Siji
Cheng, Hao
author_facet Jiang, Xiaoyun
Ye, Jun
Wu, Xia
Zhu, Jiang
Chen, Siji
Cheng, Hao
author_sort Jiang, Xiaoyun
collection PubMed
description BACKGROUND: Hypereosinophilic dermatitis (HED) is a subtype of hypereosinophilic syndrome (HES). Glucocorticoids are preferred for treatment but carry substantial side effect profiles. Symptoms of HED may recur after systemic glucocorticoid tapering. As an interleukin-4 receptor (IL-4Rα) monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), dupilumab might be an efficacious adjuvant therapy for HED. METHOD: We report a young male diagnosed with HED who suffered from erythematous papules with pruritus for over five years. Once reducing the dosage of glucocorticoid was, his skin lesions relapsed. RESULTS: After using dupilumab, the patient’s condition significantly improved with the glucocorticoid dosing decreased successfully. CONCLUSION: In conclusion, we report a new application of dupilumab in HED patients, especially with difficulties in reducing the glucocorticoid dose.
format Online
Article
Text
id pubmed-10010203
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-100102032023-03-14 A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab Jiang, Xiaoyun Ye, Jun Wu, Xia Zhu, Jiang Chen, Siji Cheng, Hao Inflamm Res Brief Report BACKGROUND: Hypereosinophilic dermatitis (HED) is a subtype of hypereosinophilic syndrome (HES). Glucocorticoids are preferred for treatment but carry substantial side effect profiles. Symptoms of HED may recur after systemic glucocorticoid tapering. As an interleukin-4 receptor (IL-4Rα) monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), dupilumab might be an efficacious adjuvant therapy for HED. METHOD: We report a young male diagnosed with HED who suffered from erythematous papules with pruritus for over five years. Once reducing the dosage of glucocorticoid was, his skin lesions relapsed. RESULTS: After using dupilumab, the patient’s condition significantly improved with the glucocorticoid dosing decreased successfully. CONCLUSION: In conclusion, we report a new application of dupilumab in HED patients, especially with difficulties in reducing the glucocorticoid dose. Springer International Publishing 2023-03-13 2023 /pmc/articles/PMC10010203/ /pubmed/36912915 http://dx.doi.org/10.1007/s00011-023-01715-1 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Brief Report
Jiang, Xiaoyun
Ye, Jun
Wu, Xia
Zhu, Jiang
Chen, Siji
Cheng, Hao
A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab
title A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab
title_full A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab
title_fullStr A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab
title_full_unstemmed A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab
title_short A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab
title_sort case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010203/
https://www.ncbi.nlm.nih.gov/pubmed/36912915
http://dx.doi.org/10.1007/s00011-023-01715-1
work_keys_str_mv AT jiangxiaoyun acaseofcompleterecoveryinahypereosinophilicdermatitispatientwithdupilumab
AT yejun acaseofcompleterecoveryinahypereosinophilicdermatitispatientwithdupilumab
AT wuxia acaseofcompleterecoveryinahypereosinophilicdermatitispatientwithdupilumab
AT zhujiang acaseofcompleterecoveryinahypereosinophilicdermatitispatientwithdupilumab
AT chensiji acaseofcompleterecoveryinahypereosinophilicdermatitispatientwithdupilumab
AT chenghao acaseofcompleterecoveryinahypereosinophilicdermatitispatientwithdupilumab
AT jiangxiaoyun caseofcompleterecoveryinahypereosinophilicdermatitispatientwithdupilumab
AT yejun caseofcompleterecoveryinahypereosinophilicdermatitispatientwithdupilumab
AT wuxia caseofcompleterecoveryinahypereosinophilicdermatitispatientwithdupilumab
AT zhujiang caseofcompleterecoveryinahypereosinophilicdermatitispatientwithdupilumab
AT chensiji caseofcompleterecoveryinahypereosinophilicdermatitispatientwithdupilumab
AT chenghao caseofcompleterecoveryinahypereosinophilicdermatitispatientwithdupilumab

Ejemplares similares